Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.

The Company’s key products are Feraccru and PT20, one commercially available and one late-stage pharmaceutical for the treatment of iron deficiency anaemia and systemic phosphate accumulation.